Quote | Tenaya Therapeutics Inc. (NASDAQ:TNYA)
Last: | $4.34 |
---|---|
Change Percent: | 3.33% |
Open: | $4.27 |
Close: | $4.20 |
High: | $4.38 |
Low: | $4.21 |
Volume: | 12,081 |
Last Trade Date Time: | 05/13/2024 03:00:00 am |
News | Tenaya Therapeutics Inc. (NASDAQ:TNYA)
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that i...
2024-03-18 16:53:54 ET More on Tenaya Therapeutics Seeking Alpha’s Quant Rating on Tenaya Therapeutics Historical earnings data for Tenaya Therapeutics Financial information for Tenaya Therapeutics Read the full article on Seeking Alpha For fur...
Message Board Posts | Tenaya Therapeutics Inc. (NASDAQ:TNYA)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Tenaya Therapeutics Inc. Company Name:
TNYA Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company wi...
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that i...
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from R...